scholarly journals Treatment with Ipilimumab: A Case Report of Complete Response in a Metastatic Malignant Melanoma Patient

2013 ◽  
Vol 6 (2) ◽  
pp. 285-288 ◽  
Author(s):  
Alfredo Addeo ◽  
Ciro Roberto Rinaldi
Keyword(s):  
Case Report ◽  
Malignant Melanoma ◽  
Melanoma Patient ◽  
Complete Response ◽  
Metastatic Malignant Melanoma ◽  
Malignant Melanoma Patient

scholarly journals A case report of using nivolumab for a malignant melanoma patient with rheumatoid arthritis

2016 ◽  
Vol 5 (4) ◽  
pp. 192-196
Author(s):  
Shun-Ichiro Kageyama ◽  
Shigeo Yamaguchi ◽  
Shin Ito ◽  
Yoshiyuki Suehara ◽  
Tsuyoshi Saito ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Case Report ◽  
Malignant Melanoma ◽  
Melanoma Patient ◽  
Malignant Melanoma Patient

Aggressive metastatic malignant melanoma of vagina: A case report

2018 ◽  
Vol 02 (01) ◽  
Author(s):  
Satyajeet Rath ◽  
Sambit Swarup Nanda ◽  
Kamal Sahni ◽  
Abhay Pratap Singh
Keyword(s):  
Case Report ◽  
Malignant Melanoma ◽  
Metastatic Malignant Melanoma

scholarly journals Metastatic Malignant Melanoma With Occult Primary Presenting as Breast Mass: A Case Report and Literature Review

Cureus ◽  
2021 ◽  
Author(s):  
Rebecca M Harsten ◽  
Rebecca Fisher ◽  
Nazar Al-Sanjari ◽  
Philip Idaewor ◽  
Abdalla Saad Abdalla Al-Zawi
Keyword(s):  
Case Report ◽  
Malignant Melanoma ◽  
Literature Review ◽  
Metastatic Malignant Melanoma ◽  
Breast Mass

scholarly journals Eruptive melanocytic nevi heralding the diagnosis of metastatic malignant melanoma: A case report

2015 ◽  
Vol 1 (2) ◽  
pp. 74-76 ◽  
Author(s):  
Nour Kibbi ◽  
Stephan Ariyan ◽  
Frederick Slogoff ◽  
Rossitza Lazova ◽  
Jennifer Nam Choi
Keyword(s):  
Case Report ◽  
Malignant Melanoma ◽  
Metastatic Malignant Melanoma ◽  
Melanocytic Nevi

PS02.182: EFFECTIVENESS OF ANTI-PD-1 ANTIBODY MONOTHERAPY FOR THE PRIMARY MALIGNANT MELANOMA OF THE ESOPHAGUS: A CASE REPORT

2018 ◽  
Vol 31 (Supplement_1) ◽  
pp. 173-174
Author(s):  
Hiroto Muroi ◽  
Masanobu Nakajima
Keyword(s):  
Case Report ◽  
Malignant Melanoma ◽  
Conflicts Of Interest ◽  
Complete Response ◽  
Primary Malignant Melanoma ◽  
Innovative Strategies ◽  
First Case ◽  
Positron Emission ◽  
Programmed Death ◽  
Programmed Death 1

Abstract Background Primary malignant melanoma of the esophagus (PMME) is extraordinarily rare with a high prevalence of malignancy and poor prognosis, and a standard therapy remains to be established. Since conventional therapeutic methods have been limited in their effects on treatment outcomes, innovative strategies for treating PMME are being explored, especially molecular targeting strategies. The programmed death 1 (PD-1) protein/programmed death ligand-1(PD-L1) inhibitor nivolumab is a promising agent for various cancers. To our knowledge, this is the first case report of PMME where a complete response was achieved using nivolumab. Methods We report an 80-year-old woman who was diagnosed with PMME with bone metastasis and lymph node metastases. Although dacarbazine combined chemotherapy was performed and continued for six cycles, the primary tumor deteriorated and liver metastases appeared. The patient then received nivolumab monotherapy (2 mg/kg, once every three weeks). Results After three cycles, nivolumab monotherapy for PMME resulted in a complete response as shown by positron emission tomography, computed tomography, and esophagogastroduodenoscopy. Conclusion In our case, nivolumab exerted a curative effect on PMME, thus suggesting that nivolumab can be effective in the treatment of this rare disease. Disclosure All authors have declared no conflicts of interest.

METASTATIC MALIGNANT MELANOMA IN THE HAND MUSCLE — A CASE REPORT

Hand Surgery ◽  
2000 ◽  
Vol 05 (01) ◽  
pp. 69-72 ◽  
Author(s):  
Hirokazu Tochigi ◽  
Yasushi Nakao ◽  
Yukio Horiuchi ◽  
Yoshiaki Toyama
Keyword(s):  
Case Report ◽  
Malignant Melanoma ◽  
Metastatic Malignant Melanoma ◽  
Hand Muscle

Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy.

1995 ◽  
Vol 13 (12) ◽  
pp. 2895-2899 ◽  
Author(s):  
A Y Bedikian ◽  
G R Weiss ◽  
S S Legha ◽  
H A Burris ◽  
J R Eckardt ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Phase Ii ◽  
Complete Response ◽  
Metastatic Malignant Melanoma ◽  
Fluid Retention ◽  
Maximal Response ◽  
Hematologic Toxicity ◽  
Hypersensitivity Reactions ◽  
Cutaneous Toxicity ◽  
Cutaneous Toxicities

PURPOSE A phase II study was undertaken to determine the efficacy of docetaxel in patients with metastatic malignant melanoma. PATIENTS AND METHODS Between June 1992 and March 1994, 40 patients with metastatic malignant melanoma and no prior chemotherapy were treated with docetaxel 100 mg/m2 administered intravenously over 1 hour every 21 days. None of the patients had brain metastasis. Toxicity and follow-up data are provided. RESULTS One patient had a histologically confirmed complete response that lasted for 14+ months. Four patients had partial responses, bringing the overall response rate to 12.5% (95% confidence interval [CI], 6% to 30%). A patient with a partial response had a single chest-wall metastasis and was rendered free of disease surgically after a maximal response to docetaxel and remained free of tumor recurrence after 18+ months. Tumor was stabilized in 22 patients. The overall median survival time was 13 months. The main hematologic toxicity was neutropenia, which was severe but transient. Peripheral neuropathy was the limiting nonhematologic toxicity in three patients. Other important toxicities included cutaneous toxicity, fluid retention, oral mucositis, and hypersensitivity reactions. Preadministration of dexamethasone and diphenhydramine reduced the incidence of hypersensitivity reactions, cutaneous toxicities, and fluid retention. CONCLUSION Docetaxel has definite but low-level activity against malignant melanoma. Further investigation of this drug should be conducted in multidrug combination programs.

Sign in / Sign up

Export Citation Format

Share Document